Phase 2 Start
GHRS: Phase2_Start: A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy
October 31, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 31, 2026
- Company
- GH Research PLC (GHRS)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start
Phase2_Start: A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy
- Company
- GH Research PLC (GHRS)
Other upcoming events for GHRS
Phase 3 StartPhase3_Start: Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low Back PaiN Treatment: VIBRANT
Phase 3 StartPhase3_Start: Safety and Efficacy of Ivarmacitinib Versus Glucocorticoids in Patients With Mild-to-Moderate Systemic Lupus Erythematosus: A Randomized, Double-Blind, Noninferiority Clinical Trial
Phase 3 StartPhase3_Start: A Phase 3, Single-Arm, Open-Label, Long-Term Extension Study To Evaluate The Safety And Efficacy Of Enpatoran In Participants With Active Cutaneous Manifestations Of Lupus Erythematosus With Or Without Systemic Disease Receiving Standard Of Care [Elowen-LTE]
Phase 2 StartPhase2_Start: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Inadequately Controlled Moderate to Severe Asthma
Phase 1 StartPhase1_Start: Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders